AstraZeneca Korea announced that type 2 diabetes treatment 'Forxiga' will be subject to health insurance benefit

Published: 2014-09-01 09:16:18

Updated: 2014-09-01 09:16:18

As Sodium-glucose co transporter 2 (SGLT-2) Inhibitors series diabetes treatment was subject to health insurance benefits, all stages of diabetes patients in domestic were able to get a new treatment option.

AstraZeneca Korea announced that type 2 diabetes treatment 'Forxiga (ingredient : dapagliflozin)' will be subject to health insurance benefits from September 1 according to the applicable ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.